专题：Histone Deacetylase Inhibitors Research

This cluster of papers explores the role of histone deacetylases (HDACs) in regulating cellular functions, gene expression, and epigenetic modifications. It covers the use of HDAC inhibitors in cancer therapy, their impact on neurodegenerative disorders, and their involvement in protein complexes and enzymatic activity.
最新文献
Histone deacetylases and cell-cycle regulators orchestrate cell-identity transitions during Arabidopsis root regeneration

article Full Text OpenAlex

CBP-IDRs regulate acetylation and gene expression

article Full Text OpenAlex

Lactate metabolism and protein lactylation in cancer

article Full Text OpenAlex

Redox-Guided Epigenetic Signaling in Cancer: miRNA–DNMT Feedback Loops as Epigenetic Memory Modulates

article Full Text OpenAlex

Targeted Protein Degradation in Cancer: PROTACs, New Targets, and Clinical Mechanisms

article Full Text OpenAlex

Discovery of Potent HDAC6-Selective Inhibitors Based on Artemisinin: Design, Synthesis, and Antitumor Evaluation

article Full Text OpenAlex

Discovery of Highly Selective AKR1C3 Inhibitors to Overcome EGFR C797S-Mediated Osimertinib Resistance in Non-Small Cell Lung Cancer

article Full Text OpenAlex

SIRT2-mediated deacetylation of LCK governs the magnitude of T cell receptor signaling

article Full Text OpenAlex

A review of pharmacogenomics in the individualization of pharmacological treatment: present and future

article Full Text OpenAlex

The Diverse Effect of HDAC Inhibitors: Sodium Butyrate and Givinostat on Microglia Polarization After Hypoxia-Ischemia In Vitro

article Full Text OpenAlex

近5年高被引文献
Modulation of cellular processes by histone and non-histone protein acetylation

review Full Text OpenAlex 871 FWCI69.2467

Class I histone deacetylases (HDAC1–3) are histone lysine delactylases

article Full Text OpenAlex 649 FWCI47.8406

Meta-hallmarks of aging and cancer

review Full Text OpenAlex 508 FWCI91.7918

Myeloid-derived suppressor cells: an emerging target for anticancer immunotherapy

review Full Text OpenAlex 456 FWCI36.0516

The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia

article Full Text OpenAlex 447 FWCI126.7336

Rational combinations of targeted cancer therapies: background, advances and challenges

review Full Text OpenAlex 442 FWCI33.3667

Epigenetic regulation in metabolic diseases: mechanisms and advances in clinical study

review Full Text OpenAlex 411 FWCI61.4318

Signaling pathways in Parkinson’s disease: molecular mechanisms and therapeutic interventions

review Full Text OpenAlex 404 FWCI57.7676

Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trials

article Full Text OpenAlex 359 FWCI101.2004

Demethylzeylasteral targets lactate by inhibiting histone lactylation to suppress the tumorigenicity of liver cancer stem cells

article Full Text OpenAlex 355 FWCI28.5143